Eton (ETON) CBO David Krempa Receives 128,985 RSU Award

What Happened

• David Krempa, Chief Business Officer of Eton Pharmaceuticals (ETON), was granted 128,985 performance‑vested restricted stock units (RSUs) on 2026-07-31. The award is reported as a derivative acquisition (code A) at $0.00 (no cash paid at grant).
• Each RSU represents the right to one share if and when the award vests. The filing reports the full, maximum number of shares issuable (128,985).

Key Details

• Transaction date and filing: Grant dated 2026-07-31; Form 4 filed 2026-08-04 (timely within SEC reporting window).
• Instrument/price: 128,985 RSUs granted, reported acquisition price $0.00 (standard for RSU grants).
• Vesting condition: Award vests in full only if the closing price of ETON equals or exceeds $72.36 for one trading day at any time before July 31, 2029. If the market condition is not met by that date, the award is forfeited in full.
• Number reported: The filing reflects the maximum and only number of shares issuable; there is no graded/threshold schedule—it's all or nothing based on the market condition.
• Shares owned after transaction: Not disclosed in this filing.
• Filing agent: The reporting person authorized another named individual to file this Form 4 on their behalf.

Context

• These are performance‑based long‑term incentive awards, not an immediate purchase or sale of shares. They become shares only if the specified market condition is met before the deadline.
• Such grants are common for executive compensation and do not necessarily indicate the insider is buying or selling stock today.